Seven Eight Capital’s Harmony Biosciences HRMY Stock Holding History

Seven Eight Capital’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,736	Closed	-$250K	–	707
2023 Q4	$250K	Buy	+7,736	New	+$216K	0.03%	550

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Seven Eight Capital's HRMY Position: Q1 2024 in Review

Seven Eight Capital sold out of Harmony Biosciences (HRMY) in Q1 2024, closing a stake of 7,736 shares — an estimated $250K sold.

Seven Eight Capital first reported a position in HRMY in Q4 2023 and held it in 1 quarter. The position peaked at $250K in Q4 2023. 208 funds tracked by Wall St. Rank hold HRMY as of Q1 2024.

Seven Eight Capital reported no remaining Harmony Biosciences position as of Q1 2024 after selling out during the quarter.
Seven Eight Capital sold 7,736 Harmony Biosciences shares in Q1 2024, an estimated $250K.
Seven Eight Capital first reported a position in Harmony Biosciences in Q4 2023 and held it in 1 quarter.
Seven Eight Capital's Harmony Biosciences position peaked at $250K in Q4 2023.
208 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2024.

Based on Seven Eight Capital's 13F filing for Q1 2024, filed 13 May 2024.